课题基金 / 基金详情

BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC

BCR-ABL TARGET IDENTIFICATION IN THE LEUKEMOGENIC
白血病中的 BCR-ABL 靶标识别
批准号:
2668016
负责人:
Ruibao Ren
金额:
$28.37万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-05-07 至 2001-02-28

项目摘要

项目成果

Ruibao Ren的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自调查人员的摘要) 目的阐明bcr-abl的分子机制。 癌基因在慢性粒细胞白血病(CML)的发病机制中起作用。 Bcr-abl癌基因是通过染色体易位产生的, 融合部分断点簇区(BCR)基因和大部分 ABL基因。该项目的重点是BCR-Abl与 其他蛋白质。BCR-Abl中的Abl酪氨酸激酶活性是必需的 对于肿瘤转化,表明Abl诱导白血病 通过目标蛋白的磷酸化。任博士的初步数据 提示Abl通过蛋白质-蛋白质方式招募特定底物 由其非催化结构域介导的相互作用。任博士已经展示了 Bcr-Abl与Abl结合蛋白Grb2共表达 在小鼠身上引发类似慢性粒细胞白血病的疾病。因此,他假设 ABPs在调节和调节肿瘤发生中起着重要作用 Abl.在这个项目中,他将进一步确定来自 白血病细胞,并研究蛋白-蛋白的作用 Bcr-Abl致癌功能的相互作用。长期的 目的是确定bcr-Abl的致癌功能 是由其结合蛋白调控和/或介导的,如果是,是否 控制这些因素可以减轻bcr-abl的恶性潜能。 互动。这些信息将有助于阐明导致白血病的原因 Bcr-Abl激活的通路有助于开发治疗药物 人类白血病。因此,该项目的具体目标如下 如下:(1)检验Grb2或Grb2关联的假设 BCR-Abl的转换需要具有BCR-Abl的其他ABP 通过检测bcr-abl基因突变对ABP的影响- 对肿瘤转化的约束;(2)检验假设 慢性粒细胞白血病患者的造血系细胞含有 通过识别BCR-Abl的潜在靶点 CML细胞;(3)检验假设,恶性潜能 可以通过中断BCR-Abl之间的相互作用来缓解BCR-Abl 和反式ABPs通过检测ABPs或ABPs过表达的能力 它们的突变多肽可以阻止细胞转化。
英文摘要
DESCRIPTION: (adapted from the investigator's abstract) The broad objective is to elucidate the molecular mechanism by which the bcr-abl oncogene acts in the pathogenesis of chronic myelogenous leukemia (CML). The bcr-abl oncogene is created by a chromosomal translocation, which fuses a portion of the breakpoint cluster region (bcr) gene and most of the abl gene. The project focuses on the interaction of Bcr-Abl with other proteins. The Abl tyrosine kinase activity in Bcr-Abl is required for the neoplastic transformation, indicating that Abl induces leukemia through phosphorylation of target proteins. Dr. Ren's preliminary data indicate that Abl recruits specific substrates via protein-protein interactions mediated by its non-catalytic domains. Dr. Ren has shown that coexpression of Bcr-Abl and the Abl-binding protein (ABP) Grb2 induces a CML-like disease in mice. Therefore, he hypothesizes that the ABPs play important roles in regulating and mediating the oncogenic functions of Abl. In this project, he will further identify ABPs from the leukemic cells, and investigate the effect of the protein-protein interactions on the oncogenic function of Bcr-Abl. The long-term objectives are to determine whether the oncogenic function of Bcr-Abl is regulated and/or mediated by its binding proteins, and if so, whether the malignant potential of Bcr-Abl can be mitigated by controlling these interactions. Such information will help to elucidate the leukemogenic pathway activated by Bcr-Abl and help to develop therapeutic drugs for human leukemia. Accordingly, the specific aims of the project are as follows: (1) To test the hypothesis that the association of Grb2 or other ABPs with Bcr-Abl is required for the transformation of Bcr-Abl via examining the effect of the mutations in Bcr-Abl that interrupt ABP- binding on neoplastic transformation; (2) To test the hypothesis that cells of hematopoietic lineage derived from CML patients contain a unique set of ABPs by identifying the potential targets of Bcr-Abl from CML cells; (3) To test the hypothesis that the malignant potential of Bcr-Abl can be mitigated by interrupting the interaction between Bcr-Abl and ABPs in trans by examining the ability of overexpression of ABPs or their mutant polypeptides to block cellular transformation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ras signaling in leukemogenesis
  • 批准号:
    7815738
  • 项目类别:
  • 资助金额:
    $1.75万
  • 财政年份:
    2009
  • 负责人:
    Ruibao Ren
  • 依托单位:
Ras signaling in leukemogenesis
  • 批准号:
    7360320
  • 项目类别:
  • 资助金额:
    $34.1万
  • 财政年份:
    2007
  • 负责人:
    Ruibao Ren
  • 依托单位:
Ras signaling in leukemogenesis
  • 批准号:
    7214339
  • 项目类别:
  • 资助金额:
    $34.11万
  • 财政年份:
    2007
  • 负责人:
    Ruibao Ren
  • 依托单位:
Ras signaling in leukemogenesis
  • 批准号:
    7581044
  • 项目类别:
  • 资助金额:
    $34.28万
  • 财政年份:
    2007
  • 负责人:
    Ruibao Ren
  • 依托单位:
海外基金